Search alternatives:
teer decrease » greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 a » 50 _ (Expand Search), 50 μ (Expand Search), 50 c (Expand Search)
teer decrease » greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 a » 50 _ (Expand Search), 50 μ (Expand Search), 50 c (Expand Search)
-
941
-
942
-
943
-
944
-
945
-
946
-
947
-
948
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
949
-
950
-
951
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
952
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
953
-
954
-
955
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
956
-
957
-
958
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
959
-
960